Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome



Status:Terminated
Conditions:Neurology
Therapuetic Areas:Neurology
Healthy:No
Age Range:6 - 18
Updated:4/5/2019
Start Date:October 17, 2018
End Date:February 18, 2019

Use our guide to learn which trials are right for you!

Open-Label Rollover Study for Continuing NBI-98854 Administration for the Treatment of Pediatric Subjects With Tourette Syndrome

This is an open-label, rollover study to collect long-term safety, tolerability, and
investigator- and participant-reported pharmacodynamic (PD) data after chronic administration
of NBI-98854 in pediatric participants with Tourette Syndrome (TS), as well as to provide
open-label access to NBI-98854 for the treatment of TS for pediatric participants who have
taken part in a Phase 2 NBI-98854 study.


Inclusion Criteria:

1. Have a clinical diagnosis of Tourette Syndrome (TS)

2. Have participated in the NBI-98854-TS2004 or NBI 98854-TS2005 Phase 2 studies

3. If using maintenance medication(s) for TS and/or TS spectrum diagnoses (e.g.
obsessive-compulsive disorder [OCD], Attention-Deficit Hyperactivity Disorder [ADHD]),
be on stable doses

4. Be in good general health

5. Subjects of childbearing potential who do not practice total abstinence must agree to
use hormonal or two forms of nonhormonal contraception (dual contraception)
consistently during the screening, treatment and follow-up periods of the study

Exclusion Criteria:

1. Have an active, clinically significant unstable medical condition within 1 month
before screening

2. Have a known history of long QT syndrome or cardiac arrhythmia

3. Have a known history of neuroleptic malignant syndrome

4. Have a cancer diagnosis within 3 years prior to screening (some exceptions allowed)

5. Have an allergy, hypersensitivity, or intolerance to VMAT2 inhibitors

6. Have a blood loss ≥250 mL or donated blood within 56 days, or donated plasma within 7
days, before the start of the study

7. Have a known history of substance dependence, substance (drug) or alcohol abuse within
3 months before the start of the study

8. Have a significant risk of suicidal or violent behavior

9. Have received an investigational drug within 30 days before the start of the study or
plan to use an investigational drug (other than NBI-98854) during the study

10. Are currently participating in another NBI-98854 clinical study

11. Are pregnant (for females)
We found this trial at
10
sites
3401 North Central Avenue
Chicago, Illinois 60634
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Anaheim, California 92805
?
mi
from
Anaheim, CA
Click here to add this to my saved trials
3410 Worth Street
Dallas, Texas 75243
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Gulf Breeze, Florida 32561
?
mi
from
Gulf Breeze, FL
Click here to add this to my saved trials
Hialeah, Florida 33012
?
mi
from
Hialeah, FL
Click here to add this to my saved trials
Houston, Texas 77058
?
mi
from
Houston, TX
Click here to add this to my saved trials
Lincoln, Nebraska 68526
?
mi
from
Lincoln, NE
Click here to add this to my saved trials
Naperville, Illinois 60563
?
mi
from
Naperville, IL
Click here to add this to my saved trials
San Diego, California 92108
?
mi
from
San Diego, CA
Click here to add this to my saved trials
San Juan, 00926
?
mi
from
San Juan,
Click here to add this to my saved trials